Effectiveness and cost-effectiveness of general immunisation of infants and young children with the heptavalent conjugated pneumococcal vaccine

BACKGROUND: The European Agency for the Evaluation of Medicinal Products (EMEA) granted market authorisation to the heptavalent pneumococcal vaccine Prevenar (Wyeth) in the year 2001. The indication of Prevenar is the active immunisation of infants and young children under the age of two against inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Antony, Katja, Pichlbauer, Ernest, Stürzlinger, Heidi
Formato: Texto
Lenguaje:English
Publicado: German Medical Science 2005
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3011321/
https://www.ncbi.nlm.nih.gov/pubmed/21289926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3011321/
https://www.ncbi.nlm.nih.gov/pubmed/21289926

Ejemplares similares